RT @VMisrai: https://t.co/vHNczHO5SL Laser safety/efficacy or clopidogrel-resistance? ⚖️ Our editorial comment published in @wjurol with H.…
RT @VMisrai: https://t.co/vHNczHO5SL Laser safety/efficacy or clopidogrel-resistance? ⚖️ Our editorial comment published in @wjurol with H.…
RT @VMisrai: https://t.co/vHNczHO5SL Laser safety/efficacy or clopidogrel-resistance? ⚖️ Our editorial comment published in @wjurol with H.…
RT @VMisrai: https://t.co/vHNczHO5SL Laser safety/efficacy or clopidogrel-resistance? ⚖️ Our editorial comment published in @wjurol with H.…
RT @VMisrai: https://t.co/vHNczHO5SL Laser safety/efficacy or clopidogrel-resistance? ⚖️ Our editorial comment published in @wjurol with H.…
RT @VMisrai: https://t.co/vHNczHO5SL Laser safety/efficacy or clopidogrel-resistance? ⚖️ Our editorial comment published in @wjurol with H.…
RT @VMisrai: https://t.co/vHNczHO5SL Laser safety/efficacy or clopidogrel-resistance? ⚖️ Our editorial comment published in @wjurol with H.…
https://t.co/vHNczHO5SL Laser safety/efficacy or clopidogrel-resistance? ⚖️ Our editorial comment published in @wjurol with H.Chabonneau @Dr_KevinZorn @BPeyronnet @AtulPathak31 https://t.co/OM924HDTl6
Safety and feasibility of #HoLEP for the treatment of #BPO in patients receiving dual antiplatelet treatment https://t.co/B5ctwuoofc via @wjurol #EEP #UroBPH https://t.co/rBwhUuSzIq